Original articles

Misdiagnosis by whole exome sequencing in progressive myoclonic ataxia consanguineous families: causes and strategies

Expand
  • 1. Department of Laboratory Medicine, The Second Affiliated Hospital to Fujian University of Tradition Chinese Medicine, Fujian Fuzhou 350003, China
    2. Department of Neurology, the First Affiliated Hospital of Fujian Medical University, Fujian Fuzhou 350005, China

Received date: 2022-08-23

  Online published: 2022-11-07

Abstract

Objective: To investigate the causes and strategies of missed diagnosis of progressive myoclonic ataxia (PMA) consanguineous families by whole exome sequencing (WES). Methods: Five PMA consanguineous families with no disease causative variants detected by WES were enrolled, and homozygosity mapping and haplotype analysis for locating disease related region were performed. Further combined with myoclonus and ataxia phenotypes, the possible pathogenic genes were identified. Sanger sequencing was used to verify the candidate mutation and perfomed family co-segregation in five families. Finally, the reasons for missed diagnosis were analyzed by tracing to the SAM and BAM files from WES alignment process. Results: By homozygous regional mapping and reanalysis of WES, 5 families with progressive myoclonic ataxia were identified as sialidosis type I (ST-I) caused by homozygous mutation of NEU1 gene c.544A >G(p.S182G). It was also found that ALT contig in human genome reference sequence could cause multiple pathogenic genes including NEU1 gene to be missed during WES alignment. Conclusions: In clinical diagnosis, autosomal recessive PMA should be paid attention to ST-I which caused by NEU1 gene mutation. For families with hereditary diseases in which WES has not found pathogenic loci, the pathogenic region can be located by combining family genetic mode and genome-wide SNP chip, then the pathogenic genes can be identified by clinical manifestations analysis.

Cite this article

YANG Hui, LI Yunlu, YANG Kang, LI Shiju, HE Jin . Misdiagnosis by whole exome sequencing in progressive myoclonic ataxia consanguineous families: causes and strategies[J]. Journal of Diagnostics Concepts & Practice, 2022 , 21(04) : 456 -461 . DOI: 10.16150/j.1671-2870.2022.04.007

References

[1] Muona M, Berkovic SF, Dibbens LM, et al. A recurrent de novo mutation in KCNC1 causes progressive myo-clonus epilepsy[J]. Nat Genet, 2015, 47(1):39-46.
[2] Marseille Consensus Group. Classification of progressive myoclonus epilepsies and related disorders[J]. Ann Neurol, 1990, 28(1):113-116.
[3] van der Veen S, Zutt R, Elting JWJ, et al. Progressive myoclonus ataxia: time for a new definition?[J]. Mov Disord, 2018, 33(8):1281-1286.
[4] Rossi M, van der Veen S, Merello M, et al. Myoclonu-sataxia syndromes: a diagnostic approach[J]. Mov Disord Clin Pract, 2020, 8(1):9-24.
[5] Kherraf ZE, Cazin C, Bouker A, et al. Whole-exome sequencing improves the diagnosis and care of men with non-obstructive azoospermia[J]. Am J Hum Genet, 2022, 109(3):508-517.
[6] Gabriel H, Korinth D, Ritthaler M, et al. Trio exome sequencing is highly relevant in prenatal diagnostics[J]. Prenat Diagn, 2022, 42(7):845-851.
[7] Alkuraya FS. Discovery of rare homozygous mutations from studies of consanguineous pedigrees[J]. Curr Protoc Hum Genet, 2012,Chapter 6:Unit6.12.
[8] Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses[J]. Am J Hum Genet, 2007, 81(3):559-575.
[9] Hamilton A, Tétreault M, Dyment DA, et al. Concordance between whole-exome sequencing and clinical Sanger sequencing: implications for patient care[J]. Mol Genet Genomic Med, 2016, 4(5):504-512.
[10] Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next-generation sequencing technologies[J]. Nat Rev Genet, 2016, 17(6):333-351.
[11] Ma X, Shao Y, Tian L, et al. Analysis of error profiles in deep next-generation sequencing data[J]. Genome Biol, 2019, 20(1):50.
[12] Ross MG, Russ C, Costello M, et al. Characterizing and measuring bias in sequence data[J]. Genome Biol, 2013, 14(5):R51.
[13] Lelieveld SH, Spielmann M, Mundlos S, et al. Comparison of exome and genome sequencing technologies for the complete capture of protein-coding regions[J]. Hum Mutat, 2015, 36(8):815-822.
[14] Kong SW, Lee IH, Liu X, et al. Measuring coverage and accuracy of whole-exome sequencing in clinical context[J]. Genet Med, 2018, 20(12):1617-1626.
[15] Reis CS, Quental S, Fernandes S, et al. Whole-exome sequencing targeting a gene panel for sensorineural hearing loss: the first portuguese cohort study[J]. Cytogenet Genome Res, 2022, 162(1-2):1-9.
[16] Haarman AEG, Thiadens AAHJ, van Tienhoven M, et al. Whole exome sequencing of known eye genes reveals genetic causes for high myopia[J/OL]. Hum Mol Genet, 2022[2022-08-23]. https://pubmed.ncbi.nlm.nih.gov/35567543/.
[17] Sreenivasan R, Bell K, van den Bergen J, et al. Whole exome sequencing reveals copy number variants in individuals with disorders of sex development[J]. Mol Cell Endocrinol, 2022, 546:111570.
[18] Mandelker D, Schmidt RJ, Ankala A, et al. Navigating highly homologous genes in a molecular diagnostic setting: a resource for clinical next-generation sequencing[J]. Genet Med, 2016, 18(12):1282-1289.
[19] Cao YN, Li L, Xu M, et al. The ChinaMAP analytics of deep whole genome sequences in 10 588 individuals[J]. Cell Res, 2020, 30(9):717-731.
Outlines

/